Anxiety and somatic symptoms as predictors of treatment-related adverse events in major depressive disorder. Academic Article uri icon

Overview

abstract

  • The purpose of this study was to examine the relationship between the degree of anxiety or somatic symptoms present before treatment with the subsequent diagnosis of treatment-related adverse events (TRAEs) in patients with major depressive disorder (MDD) enrolled in an 8-week open trial of fluoxetine (20 mg). Baseline symptom questionnaires (SQ) were completed by 170 MDD patients enrolled in the trial. We then tested whether pre-treatment scores for anxiety and somatic symptoms predicted (1) whether patients were subsequently diagnosed with TRAEs; (2) whether they were subsequently diagnosed with moderate or severe TRAEs; or (3) whether a greater number of TRAEs were diagnosed during the trial. We found that depressed patients who presented with prominent somatic symptoms were significantly more likely to report at least one moderate or severe side effect during the course of treatment, but not more likely to report a greater number of side effects. Pre-treatment anxiety was not related to the development of side effects.

publication date

  • May 30, 2004

Research

keywords

  • Anxiety
  • Depressive Disorder, Major
  • Fluoxetine
  • Selective Serotonin Reuptake Inhibitors
  • Somatoform Disorders

Identity

Scopus Document Identifier

  • 2442591791

Digital Object Identifier (DOI)

  • 10.1016/j.psychres.2004.02.007

PubMed ID

  • 15157754

Additional Document Info

volume

  • 126

issue

  • 3